Moreover, our data indicate that combined therapy of the proteasome inhibitor carfilzomib and targeting AXL (upstream of FLT3) might be a promising treatment option particularly in FLT3-ITD positive AML. This evidence concerns the gene AXL and acute myeloid leukemia.